Celsion (NASDAQ:CLSN) Share Price Passes Above Two Hundred Day Moving Average of $1.94

Shares of Celsion Co. (NASDAQ:CLSN) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.94 and traded as high as $1.60. Celsion shares last traded at $1.59, with a volume of 635 shares traded.

A number of brokerages recently weighed in on CLSN. ValuEngine upgraded Celsion from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Brookline Capital Management restated a “buy” rating on shares of Celsion in a research report on Thursday, July 25th. Finally, Zacks Investment Research raised Celsion from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, August 20th.

The company has a market capitalization of $33.15 million, a price-to-earnings ratio of -2.19 and a beta of 1.92. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.47 and a current ratio of 3.47. The business has a 50 day moving average price of $1.75 and a 200-day moving average price of $1.94.

Celsion (NASDAQ:CLSN) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. As a group, equities analysts predict that Celsion Co. will post -1.09 EPS for the current fiscal year.

A hedge fund recently raised its stake in Celsion stock. Vanguard Group Inc. boosted its position in Celsion Co. (NASDAQ:CLSN) by 43.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 704,651 shares of the biotechnology company’s stock after buying an additional 211,779 shares during the period. Vanguard Group Inc. owned approximately 3.44% of Celsion worth $1,282,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.53% of the company’s stock.

Celsion Company Profile (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

See Also: Gap Up Stocks

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.